Trends in antihypertensive drug advertising, 1985-1996.

BACKGROUND Over the past decade, calcium channel blockers (CCBs) and ACE inhibitors have been used increasingly in the treatment of hypertension. In contrast, beta-blocker and diuretic use has decreased. It has been suggested that pharmaceutical marketing has influenced these prescribing patterns. No objective analysis of advertising for antihypertensive therapies exists, however. METHODS AND RESULTS We reviewed the January, April, July, and October issues of the New England Journal of Medicine from 1985 to 1996 (210 issues). The intensity of drug promotion was measured as the proportion of advertising pages used to promote a given medication. Statistical analyses used the chi2 test for trend. Advertising for CCBs increased from 4.6% of advertising pages in 1985 to 26.9% in 1996, while advertising for beta-blockers (12.4% in 1985 to 0% in 1996) and diuretics (4.2% to 0%) decreased (all P<0.0001). A nonsignificant increase was observed in advertising for ACE inhibitors (3.5% to 4.3%, P=0.17). Although the total number of drug advertising pages per issue decreased from 60 pages in 1985 to 42 pages in 1996 (P<0.001), the number of pages devoted to calcium channel blocker advertisements nearly quadrupled. CONCLUSIONS Increasing promotion of CCBs has mirrored trends in physician prescribing. An association between advertising and prescribing patterns could explain why CCBs have supplanted better-substantiated therapies for hypertension.

[1]  B. Psaty,et al.  Health Outcomes Associated with Antihypertensive Therapies Used as First-Line Agents: A Systematic Review and Meta-analysis , 1998 .

[2]  David Siegel,et al.  Trends in Antihypertensive Drug Use in the United States: Do the JNC V Recommendations Affect Prescribing? , 1997 .

[3]  L Goldman,et al.  Adverse Outcomes of Underuse of β-Blockers in Elderly Survivors of Acute Myocardial Infarction , 1997 .

[4]  Detection.  The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[5]  R. Weinshilboum,et al.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.

[6]  B. Psaty,et al.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.

[7]  T. Raghunathan,et al.  The risk of myocardial infarction associated with antihypertensive drug therapies. , 1995, JAMA.

[8]  J. M. Young.  The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure , 1995, AAOHN journal : official journal of the American Association of Occupational Health Nurses.

[9]  P. Whelton,et al.  Trends in pharmacologic management of hypertension in the United States. , 1995, Archives of internal medicine.

[10]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[11]  J. Gardin,et al.  Temporal patterns of antihypertensive medication use among elderly patients. The Cardiovascular Health Study. , 1993, JAMA.

[12]  Michael S. Wilkes,et al.  Pharmaceutical Advertisements in Leading Medical Journals: Experts' Assessments , 1992 .

[13]  J. Tuomilehto,et al.  Beta-blockade in the primary prevention of coronary heart disease in hypertensive patients. Review of present evidence. , 1991, Circulation.

[14]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[15]  H. Parving,et al.  Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. , 1991, BMJ.

[16]  C. Furberg.  The impact of clinical trials on clinical practice. , 1989, Arzneimittel-Forschung.

[17]  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.

[18]  R Hartley,et al.  Scientific versus commercial sources of influence on the prescribing behavior of physicians. , 1982, The American journal of medicine.